FGP
NAMS icon

Freestone Grove Partners’s NewAmsterdam Pharma NAMS Stock Holding History

Freestone Grove Partners’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,000
Closed -$96K – 1222
2026
Q1 		$96K Buy
+3,000
New +$97.7K ﹤0.01% 808

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Freestone Grove Partners's NAMS Position: Q2 2026 in Review

Freestone Grove Partners sold out of NewAmsterdam Pharma (NAMS) in Q2 2026, closing a stake of 3,000 shares — an estimated $96K sold.

Freestone Grove Partners first reported a position in NAMS in Q1 2026 and held it in 1 quarter. The position peaked at $96K in Q1 2026. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Freestone Grove Partners reported no remaining NewAmsterdam Pharma position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 3,000 NewAmsterdam Pharma shares in Q2 2026, an estimated $96K.
  • Freestone Grove Partners first reported a position in NewAmsterdam Pharma in Q1 2026 and held it in 1 quarter.
  • Freestone Grove Partners's NewAmsterdam Pharma position peaked at $96K in Q1 2026.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.